Analytical techniques for multiplex analysis of protein biomarkers

Abstract

Introduction: The importance of biomarkers for pharmaceutical drug development and clinical diagnostics is more significant than ever in the current shift toward personalized medicine. Biomarkers have taken a central position either as companion markers to support drug development and patient selection, or as indicators aiming to detect the earliest perturbations indicative of disease, minimizing therapeutic intervention or even enabling disease reversal. Protein biomarkers are of particular interest given their central role in biochemical pathways. Hence, capabilities to analyze multiple protein biomarkers in one assay are highly interesting for biomedical research. Areas covered: We here review multiple methods that are suitable for robust, high throughput, standardized, and affordable analysis of protein biomarkers in a multiplex format. We describe innovative developments in immunoassays, the vanguard of methods in clinical laboratories, and mass spectrometry, increasingly implemented for protein biomarker analysis. Moreover, emerging techniques are discussed with potentially improved protein capture, separation, and detection that will further boost multiplex analyses. Expert commentary: The development of clinically applied multiplex protein biomarker assays is essential as multi-protein signatures provide more comprehensive information about biological systems than single biomarkers, leading to improved insights in mechanisms of disease, diagnostics, and the effect of personalized medicine.

The New and the Old: Platform Cross-Validation of Immunoaffinity MASS Spectrometry versus ELISA for PromarkerD, a Predictive Test for Diabetic Kidney Disease

“…The major obstacles to this transition remain assay reproducibility and current clinical workflows which preference easy-to-use, low-cost technologies and fast turnaround times. Contrasting this, the omics revolution is highlighting the benefits of measuring multiple biomarkers simultaneously to achieve more accurate diagnoses of the disease state [19,20]. Although ELISA based platforms continue to drive current clinical practice, the assays themselves remain slow to develop, vulnerable to cross-reactivity, and difficult to multiplex.…”

Urinary Angiogenin as a Marker for Bladder Cancer: A Meta-Analysis

“…In this regard, angiogenin can be considered a fair tumor marker for BCa. One of the first clinical demonstrators of biomarker-driven BCa to higher clinical achievement was angiogenin (ANG), followed by other pathology progress and beyond [ 28 ].…”

Novel Approaches to an Integrated Route for Trisomy 21 Evaluation

“…However, single biomarkers are not likely able to serve as the best diagnostic or prognostic markers for T21 due to their limited discriminatory power. On the other hand, biomarker panels comprising multiple measured analytes provide high sensitivity and specificity for distinguishing T21 from euploid pregnancies [ 90 ].…”